12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G
Year: 2022
Type: conference-abstract
Institutions: University of Iowa, Essen University Hospital, University of Duisburg-Essen, Hôpital Européen Georges-Pompidou, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Imperial College London, Hospital Universitario 12 De Octubre, Mario Negri Institute for Pharmacological Research, Vall d'Hebron Hospital Universitari, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Royal Victoria Infirmary, Newcastle University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4397024488